Development and Characterization of Telmisartan-Loaded Nanosuspension for Enhanced Drug Delivery

Background

In this exploration, the aim was to devise and delineate a nanoscale suspension of telmisartan directed at enhancing drug delivery efficiency.

Materials and Methods

The process entailed formulating telmisartan-loaded nanosuspensions through the solvent evaporation technique, followed by a comprehensive characterization using various analytical methods.

Results

Analysis via dynamic light scattering disclosed an average particle size of 285 nanometers along with a Polydispersity Index (PDI) of 0.374, indicating a uniform dispersion of particles. Transmission electron microscopy validated the existence of evenly dispersed spherical nanoparticles. Fourier transform infrared spectroscopy confirmed the presence of expected functional groups within the formulation. Evaluation of zeta potential showed a negative value of -21.5±2.0 millivolts, suggesting favorable stability of the nanosuspension. Differential scanning calorimetry demonstrated an absence of significant interactions between the drug and accompanying components. Furthermore, in vitro drug release assessments showcased an initial rapid release of 14.8% from the optimized formulation F3 within the first 5 min, leading to a cumulative drug release of 98.2% over a period of 40 min.

Conclusion

Overall, the developed telmisartan nanosuspension exhibited promising characteristics, suggesting its potential for improved therapeutic outcomes in the treatment of cardiovascular conditions.